Skip to main content
Premium Trial:

Request an Annual Quote

TwinStrand Biosciences Lays Off 'Nearly 50 Percent' of Workforce

NEW YORK – Sequencing sample prep firm TwinStrand Biosciences has laid off close to half of its workforce, according to reports from former employees.

Since Monday, at least half a dozen former employees on the social networking site LinkedIn said they'd been laid off. Multiple people described the total number of layoffs as being "nearly 50 percent" of the company. 

According to LinkedIn, the company had at least 100 employees registered with the site.

TwinStrand did not immediately respond to a request for comment.

Seattle-based TwinStrand, a University of Washington spinout, is commercializing duplex sequencing technology, a method that matches sequencing data from complementary strands of a DNA molecule to help reduce errors, which can help identify ultra-rare genomic variants.

The firm raised $50 million in a Series B financing round in May 2021.

It licensed its duplex technology to Roche's Foundation Medicine in November 2020 and sued Guardant Health in August 2021, alleging patent infringement.

Of the employees who announced their termination on LinkedIn, about half were involved in bioinformatics or other data analysis roles.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.